Intranasal midazolam for prolonged convulsive seizures.
In order to determine the efficiency of intranasal midazolam in prolonged convulsive episodes, we conducted a prospective study in children with various types of seizures. Nine patients (six boys, three girls; age range 6 months to 9 years) with prolonged convulsions lasting more than 10 min were treated with intranasal midazolam, 0.3 mg/kg. The success rate was 100% with only one case requiring a second dose. Estimated duration of seizures was 12-30 min (mean 18.6) while mean time elapsed until cessation of seizures was 139.6 s (range 60-480). No significant adverse effects were noted except for one patient who had seizures secondary to serious CNS infection and respiratory depression after intranasal midazolam.
Kutlu
N O
NO
Department of Pediatrics, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey. onurkutlu@hotmail.com
Yakinci
C
C
Dogrul
M
M
Durmaz
Y
Y
D000281:Administration, Intranasal; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008874:Midazolam / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012640:Seizures / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D008874:Midazolam